An aging global population, rising affluence, and expanded access to eye care plus increased computer use and more effective dry eye products are expected to fuel double-digit compounded growth in the dry eye products market during the next five years. We expect much of this growth to occur in the pharmaceutical segment where new pipeline therapies are poised to join two very successful commercialized Rx products.
Our report on the dry eye products marketplace is in its fifth edition. It is a leading industry source for accurate and relevant information on all aspects of the market for dry eye treatments. We cover tear function and both classification and diagnosis of dry eye. We discuss disease prevalence and forecast dry eye cases worldwide. We examine the various treatment modalities and discuss their mechanisms of action. We forecast demand for dry eye products in units and dollars, and we analyze market shares by product category. We also discuss treatment patterns and trends, as well as strategic issues that are key to success in this large and growing market.
Our market analysis is based on surveys of ophthalmic surgeons, a proprietary database and extensive industry contacts. Our forecasts for performance detail the diverse products in the dry eye market over the next five years. And with our many years of experience in the ophthalmic industry, we remain committed to bringing independent perspective and context to the latest industry information. Our products are now available in print and in electronic formats, as well as through on-line subscriptions to maximize their value and accessibility.
In our comprehensive reports, we analyze worldwide markets using the following geographic/economic categories: the US, Western Europe, Japan, Other Wealthy Nations, China, India, Latin America, and Rest of World. This report includes market data for 2008 and we forecast market performance through 2014.
Our Report is Organized into Key Areas and Includes:
· Dry Eye Overview
· Primary Eye Care
· Diagnosis of Dry Eye
· Treatment of Dry Eye
· Prevalence of Dry Eye
· Rx Therapeutic Products
· OTC Products (Artificial Tears, Gels, and Ointments)
· Punctum Plugs
· 24 Investigational Dry Eye Therapies
· Additional Dry Eye Products
· 31 Company Profiles and Additional Company Listings
· 21 Color Tables and 17 Color Figures
Our 2009 Comprehensive Report on the Global Market for Dry Eye Products was just released in July. The report is printed in color and is spiral bound for easy reading. The price of the report is $2,700.
TABLE OF CONTENTS
INTRODUCTION
Scope of the Study
Methodology
About the Author
The Report at a Glance
EXECUTIVE SUMMARY
DRY EYE OVERVIEW
Normal Tear Function
Causes of Dry Eye
Classification of Dry Eye
Tear Deficiency
Non-Sjögren’s Tear Deficiency
Sjögren’s Syndrome Tear Deficiency
Evaporative Dry Eye
The Role of Inflammation
Hormones and Dry Eye
LASIK and Dry Eye
DIAGNOSIS OF DRY EYE
Diagnostic Staining
Tear Break-up Time (TBUT)
Schirmer Test
Clinical Examination
Dry Eye Questionnaires
New Approaches to Diagnosing Dry Eye
TREATMENT OF DRY EYE
Lubricating Drops
Nutritional Supplements
Restasis and Other Anti-inflammatory Agents
Viscoelastic Lubricants
Punctal Occlusion
Reservoirs, Pellets, etc
Associated Treatments
The Seven Principles of Dry Eye Treatment
PREVALENCE OF DRY EYE
Beaver Dam Eye Study
Salisbury, MD, Study
Melbourne Visual Impairment Project
The Canadian Dry Eye Epidemiology Study
Women’s Health Initiative
Estimating Dry Eye Prevalence
DRY EYE PRODUCTS
Global Market for Dry Eye Products
Current Market Share
COMMERCIALIZED RX THERAPEUTIC PRODUCTS
Topical Therapeutics
Allergan’s Restasis
Santen’s Hyalein
TRB Chemedica’s Vismed
Corticosteroids
Sustained Release Rx Therapeutics
Lacrisert
Systemic Agents
Daiichi Sankyo’s Exovac
Salagen’s Pilocarpine
RX PRODUCTS IN THE DEVELOPMENT PIPELINE
Anti-inflammatories and Immunomodulators
Sirion ST-603
Novagali’s Cyclokat
Zymedis’ Cyclosporin A
Lux Biosciences’ LX214
Resolvyx Pharmaceuticals’ RX-10045
ISTA Pharmaceuticals’ Xibrom
Alcon’s Vexol (rimexolone or AL-2178)
EyeGate Pharmaceuticals EGP-437
OPKO Health’s Civamide
Can-Fite BioPharma’s CF101
Lubricating Agents
Alcon/Lantibio’s Vismed
Novagali’s Cationorm
Secretagogues and Other Mucin Enhancers
Inspire’s Prolacria
Otsuka/Acucela’s Rebamipide
Lantibio’s Lancovutide
ISTA Pharmaceuticals’ Ecabet Sodium
Other Secretagogues and Mucin Enhancers
Hormone-Based Treatments
Off-Label Use
Allergan’s Androgen Tears
arGentis’ ARG101
Other Drug Candidates
Alacrity Bioscience’s ALTY-0501
Santen/Daiichi Sankyo’s Rivoglitazone
Summary Tables for Current Drug Candidates
Additional Therapeutic Approaches
Autologous Serum
Amniotic Membrane Patch
Epidermal Growth Factor (EGF)
Nerve Growth Factor (NGF)
Graveyard of Dry Eye Products
ARTIFICIAL TEARS, GELS AND OINTMENTS
Artificial Tears Classified by Packaging
Single-Dose Packaging
Multi-Use Bottles
Ointments and Gels
Artificial Tears Technology
Systane
Optive
Soothe
Blink Tears
Oasis Tears
Lubricating Tears and Gels Classified by Chemical Composition
Other Lubricating Products
PUNCTUM PLUGS
Punctal Plug Applications
Demand for Punctum Plugs
Punctum Plug Manufacturers/Distributors
Cost of Punctum Plugs
Punctum Plug Development
Punctal Plugs Manufacturers
ADDITIONAL DRY EYE PRODUCTS
Drug Delivery
NOVASORB
Cationorm
Unidoser
Eye-Instill
OptiMyst
Omega 3 Supplements
The Role of Omega-3 Fatty Acids
HydroEye SoftGels
BioTears Oral Gel Caps
TheraTears Nutrition
DRY EYE ORGANIZATIONS
Sjögren’s Syndrome Foundation
Tear Film and Ocular Surface Society
COMPANY PROFILES
EyeGate Pharma
Occulogix, Inc. (dba TearLab Corporation)
Similasan, AG